Wall Street is chewing over data on Amgen’s weight loss injection, MariTde. Meanwhile, GE HealthCare will acquire a Japanese ...

The relationship between interest rates and dividend stocks tends to follow a predictable pattern. Amgen (NASDAQ: AMGN) ...

Amgen (Nasdaq: AMGN) is investing more than $1 billion to expand its operations in Holly Springs, where the company already ...

Some people are taking tiny amounts of weight loss medications, hoping to drop pounds while avoiding side effects. Does it ...

Eli Lilly and Company LLY announced that its popular obesity drug, Zepbound (tirzepatide) demonstrated more weight loss than ...

The collaboration deal, which could be worth hundreds of millions of dollars, is a “pivotal moment” for Muna Therapeutics, a ...

The results in mice were hailed as “miraculous,” and Amgen licensed the hormone for $20 million from Rockefeller University. But its initial promise failed to pan out, as treatments mimicking leptin ...

"Platforms often promote misinformation or oversimplified solutions," one expert told Newsweek about the findings.

A doctor, bariatric surgeon and professor say that treatments other than weight-loss drugs are needed to fix the obesity ...

Bitcoin hit a key milestone on Wednesday night after a year of making inroads with the U.S. financial system and politicians.

Viking Therapeutics shows strong data with VK2735, a potential competitor to major drugs. Discover why VKTX stock is a ...

VK2735 has demonstrated superior early-stage efficacy in weight loss compared to tirzepatide, with a notably favorable safety profile and low discontinuation rates, which are crucial for commercial ...